regn7508
mAbexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Jan 3, 2023 (NCT05603195)
Timeline
Indications
Mechanism of action
- Coagulation factor XIANTAGONIST
F11 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07213778 | Phase 3 | Dec 5, 2025 | Regeneron |
| NCT07175428 | Phase 2 | Oct 20, 2025 | Regeneron |
| NCT07015905 | Phase 3 | Jun 25, 2025 | Regeneron |
| NCT06444178 | Phase 1 | Sep 30, 2024 | Regeneron |
| NCT06299111 | Phase 2 | Sep 20, 2024 | Regeneron |
| NCT06454630 | Phase 2 | Jun 27, 2024 | Regeneron |
| NCT05603195 | Phase 1 | Jan 3, 2023 | Regeneron |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 7 | 7 | 3 | 2023 |
1 organizations
Page 1 / 1